The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...

Transposon sequencing analyses reveal that among genomically diverse clinical Mycobacterium intracellulare strains and the type strain, 131 genes were comprehensively identified as universal essential ...